I have worked on IGF for several years, first for its effect on increasing the rate of twinning (multiple ovulations), and second for the stimulation of oligodendrocytes to produce myelin, which may have benefit in the prevention of autism in neonates.  Since IGF has MANY anabolic effects throughout the body, it is hard to distinguish which are local and which are systemic.

Majority of VEGF effects in vivo appears through VEGF/VEGFR-2 interactions, which generally involves VEGFR-2-positive endothelial cells. Systemic VEGF protein injection via tail vein causes quick permeability response (within minutes) in whole body vasculature, that never happens when doing local injection (into skeletal muscle, for example). When we systemically overexpressed VEGF via AAV delivery, the mouse can suffer a lot because of huge permeability response. If to do the same with just local treatment the mouse is fine, and only the treated tissue is affected. I mean permeability and angiogenic response. So, if you are aiming to induce angiogenesis without major secondary effects (which is permeability response, huge accumulation of inflammatory cells, burst of production of cytokines triggering secondary pathways) use local tissue treatment. Otherwise, interpretation of the results would be problematic.